Testing pembrolizumab alone after initial combination treatment in bladder cancer
Tests pembrolizumab alone after combination treatment in adults with metastatic urothelial cancer.
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Registry title
- Circulating Tumor DNA Response In Urothelial Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 19 Jan 2026
- Expected to end
- Mar 2029
- Type of study
- Interventional
- Treatments tested
- Pembrolizumab & Enfortumab Vedotin (PEV)
- Pembrolizumab
- Record updated
- 2 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with urothelial cancer that cannot be removed by surgery, has spread locally, or has spread to other parts of the body, and who have not yet had treatment for this stage.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Urothelial carcinoma (bladder-type cancer) that cannot be removed by surgery, is locally advanced, or is metastatic. Disease must be measurable on scans (RECIST v1.1). ECOG performance status 0, 1 or 2.
- Earlier treatment
- No earlier enfortumab vedotin or similar MMAE-based drugs. No PD-1 or PD-L1 inhibitor within 12 months. No earlier systemic treatment for advanced disease, except chemotherapy or immunotherapy after surgery with return of cancer more than 12 months later.
- Biomarker or test result
- Stored tumor tissue or a biopsy of metastatic cancer must be available for tumor-informed ctDNA testing.
Main reasons for not taking part
- Untreated brain or spinal cord (central nervous system) metastases
- Uncontrolled diabetes or grade III or worse nerve damage in hands or feet (peripheral neuropathy)
- Known active hepatitis B, hepatitis C or HIV infection
- Active autoimmune disease needing immune-suppressing treatment in the past 2 years
- Earlier donor stem cell or solid organ transplant
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Have histologically documented unresectable, locally advanced, or metastatic urothelial carcinoma
- Measurable disease according to the New Response Evaluation Criteria in Solid Tumors (RECIST v1.1)38; Participants with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy
- Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment
- Archival tumor tissue comprising muscle-invasive urothelial carcinoma, or a biopsy of metastatic urothelial carcinoma must be available for tumor-informed ctDNA analysis
- Meets Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
- Adequate hematologic and organ function (Hb ≥ 8.0 g/dL; ANC ≥ 1.5x109 cells/L; CrCl ~30 mL/min; total bilirubin ≤ 1.5 mg/dL; ALT and AST within normal limits)
Who cannot take part
- Previously received enfortumab, vedotin, or other monomethyl auristatin E (MMAE)-based ADCs
- Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor within 12 months
- Has received anti-cancer treatment with chemotherapy, biologics, or investigational agents not otherwise prohibited by exclusion criterion 1-3 that is not completed within 28 days prior to cycle 1 day 1
- Experiences ongoing clinically significant toxicity associated with prior treatment that has not resolved to ≤ Grade 1 or returned to baseline
- Is currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal). Routine antimicrobial prophylaxis is permitted
- Received radiotherapy within 2 weeks
- Received major surgery (defined as requiring general anesthesia and >24-hour inpatient hospitalization) within 2 weeks
- Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:; Participants that received neoadjuvant chemotherapy with recurrence >12 months from completion of therapy are permitted; Participants that received adjuvant chemotherapy or ICPIs therapy following cystectomy with recurrence >12 months from completion of therapy are permitted
- Has received prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days
- Has uncontrolled diabetes or ≥ grade III peripheral neuropathy
- Has known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Has history of another invasive malignancy requiring treatment within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy (excluding localized prostate cancer or basal cell carcinoma of skin or squamous cell carcinoma of the skin)
- Has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class IV within 6 months
- Known severe (≥ Grade 3) hypersensitivity to any EV excipient contained in the drug formulation of EV
- Has a history of autoimmune disease that has required systemic immunosupressive treatment in the past 2 years, or uncontrolled autoimmune disease
- Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Patient's estimated life expectancy is less than 12 weeks
- Has untreated central nervous system metastases
- Has active keratitis or corneal ulcerations
Where in United States
- OU Health Stephenson Cancer CenterOklahoma City, United StatesContact: Adanma Ayanambakkam, MDTaking people
About the trial
What the trial wants to find out
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
The group in the trial
- Pembrolizumab & Enfortumab Vedotin (PEV)Treatment being tested
Patients with metastatic urothelial carcinoma (mUC) will initiate first-line (1L) PEV therapy as the standard of care. At 24 weeks, radiographic imaging will be performed to evaluate disease status. Patients who exhibit either stable disease or ongoing radiographic response, accompanied by a ≥50% reduction in circulating tumor DNA (ctDNA) levels, will transition to pembrolizumab monotherapy as part of a treatment de-escalation strategy. Pembrolizumab will be continued until the occurrence of disease progression or unacceptable toxicity. In the event of progression or intolerance, patients will be re-challenged with first-line PEV therapy and continue treatment until completion of the study-defined treatment period.
Treatment: Pembrolizumab & Enfortumab Vedotin (PEV) and Pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Circulating Tumor DNA Response Adapted Treatment De-escalation Metastatic Urothelial Carcinoma (CT-READ)
- Plain-language title
- Testing pembrolizumab alone after initial combination treatment in bladder cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 February 2026